Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S

Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;


LEQEMBI launched in the U.S.





Second quarter revenue $2,456...

Related Keywords

Samsung Biologics ,Chuck Triano ,Samsung Bioepis ,Christophera Viehbacher ,Jack Cox ,Twitter ,Exchange Commission ,Youtube ,Biogen Inc ,Linkedin ,Net Income Attributable To Biogen Inc ,Development Expense ,Nasdaq ,Facebook ,National Coverage Determination ,Chief Executive Officer Christopher ,Total Revenue ,Three Months Ended June ,Six Months Ended June ,Muscular Atrophy ,Administrative Expense ,Acquired Intangible Assets ,Tax Rate ,Noncontrolling Interests ,Income Attributable ,Earnings Per Share ,World Revenue ,Biosimilars Product Revenue ,Product Revenue ,Contract Manufacturing ,Markets ,